Stryker Corporation SYK
Healthcare · Medical Devices · United States · S&P 500
Based on the available data, Stryker Corporation gets an algorithmic score of 58/100. It trades at 278.77 $, with a bearish technical trend (RSI 39.1) and 29.6% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Sustained revenue growth (10.8% compound annual).
- Low beta (0.59): defensive profile.
Weaknesses
- —
Fundamentals
| P/E | 28.50 |
| Forward P/E | 16.67 |
| PEG | 1.29 |
| P/B | 4.46 |
| EV/EBITDA | 16.12 |
| P/S | 4.14 |
| ROE % | 16.51 |
| ROA % | 8.16 |
| Gross margin % | 65.59 |
| Operating margin % | 27.02 |
| Net margin % | 14.43 |
| Revenue growth % (y/y) | 9.40 |
| Earnings growth % (y/y) | 44.10 |
| Revenue CAGR % | 10.83 |
| Earnings CAGR % | 11.24 |
| Debt/Equity % | 64.39 |
| Current ratio | 2.16 |
| FCF yield % | 4.01 |
| Dividend yield % | 1.26 |
| Payout % | 36.06 |
Returns
| 1 month | -15.7 % |
| 3 months | -11.5 % |
| 6 months | -14.1 % |
| YTD | -19.5 % |
| 1 year | -23.7 % |
| 3 years | +0.6 % |
| 5 years | +9.5 % |
Risk
| 1-year volatility | 29.6 % |
| Beta | 0.59 |
| 5-year max drawdown | -32.5 % |
| Sharpe 1A | -0.90 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.